{"id":222381,"date":"2026-04-20T05:51:10","date_gmt":"2026-04-20T05:51:10","guid":{"rendered":"https:\/\/www.europesays.com\/se\/222381\/"},"modified":"2026-04-20T05:51:10","modified_gmt":"2026-04-20T05:51:10","slug":"dnb-carnegie-sanker-det-motiverade-vardet-for-eql-pharma","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/se\/222381\/","title":{"rendered":"DNB Carnegie s\u00e4nker det motiverade v\u00e4rdet f\u00f6r EQL Pharma"},"content":{"rendered":"<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">DNB Carnegie s\u00e4nker sitt motiverade v\u00e4rde f\u00f6r generikabolaget EQL Pharma till 65-85 kronor (70-90) efter justerade prognoser och \u00f6kad os\u00e4kerhet p\u00e5 kort sikt, enligt en uppdragsanalys.\n <\/p>\n<p>Analyshuset s\u00e4nker ebit-prognoserna f\u00f6r de brutna r\u00e4kenskaps\u00e5ren 2025\/26, 2026\/27 och 2027\/28 med 10, 13 respektive 7 procent, fr\u00e4mst p\u00e5 grund av f\u00f6rh\u00f6jda fraktkostnader fr\u00e5n konflikten i Mellan\u00f6stern, vilket v\u00e4ntas p\u00e5g\u00e5 \u00e5tminstone fram till och med under f\u00f6rsta halv\u00e5ret 2026.\n <\/p>\n<p>Samtidigt bed\u00f6ms bolaget ha potential p\u00e5 medell\u00e5ng sikt.\n <\/p>\n<p>&#8221;\u00c4ven om effekterna p\u00e5 kort sikt delvis uppv\u00e4gs av l\u00e4gre r\u00f6relsekostnader, i linje med en n\u00e5got svagare tillv\u00e4xt och aktivitet, ser vi fortsatt positiva tillv\u00e4xtutsikter och anser att orderstocken talar f\u00f6r en fortsatt expansion. Eftersom lanseringarna under 2025\/26 ger begr\u00e4nsad medvind anser vi dock att tillv\u00e4xten i stor utstr\u00e4ckning \u00e4r beroende av nya lanseringar, vars tidpunkt fortfarande \u00e4r os\u00e4ker, vilket inneb\u00e4r en viss prognosrisk f\u00f6r 2026\/27&#8221;, skriver analyshuset.<br \/>\n <br class=\"col-start-2\"\/><\/p>\n<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">Reno Santic<br \/>\n <br class=\"col-start-2\"\/><br \/>\n Nyhetsbyr\u00e5n Finwire<br \/>\n <br class=\"col-start-2\"\/><br \/>\n <a class=\"twitter-timeline\" data-width=\"1200\" data-height=\"1000\" data-dnt=\"true\" href=\"https:\/\/twitter.com\/Finwire?ref_src=twsrc%5Etfw\" rel=\"nofollow noopener\" target=\"_blank\">Tweets by Finwire<\/a><script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script><br \/>\n <br class=\"col-start-2\"\/><br \/>\n newsroom@finwire.se<\/p>\n<p><script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script><\/p>\n","protected":false},"excerpt":{"rendered":"DNB Carnegie s\u00e4nker sitt motiverade v\u00e4rde f\u00f6r generikabolaget EQL Pharma till 65-85 kronor (70-90) efter justerade prognoser och&hellip;\n","protected":false},"author":2,"featured_media":218265,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[65],"tags":[72,70,71,17659,34,31,33,32,30],"class_list":["post-222381","post","type-post","status-publish","format-standard","has-post-thumbnail","category-ekonomi","tag-business","tag-economy","tag-ekonomi","tag-eql-pharma","tag-se","tag-svenska","tag-sverige","tag-sweden","tag-swedish"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@se\/116435477393609813","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/222381","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/comments?post=222381"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/222381\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media\/218265"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media?parent=222381"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/categories?post=222381"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/tags?post=222381"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}